세계의 카르티노이드 종양 시장 보고서(2025년)

Carcinoid Tumor Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

카르티노이드 종양 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간의 성장은 분자 표적 치료의 이용 확대 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 진단에 있어서의 AI와 머신러닝의 통합, 병용 요법으로의 시프트, 원격 의료와 원격 모니터링의 확대, 환자 중심의 케어에의 중점화, 공동 연구 활동 증가 등이 있습니다.

비만 증가는 카르티노이드 종양 시장의 성장을 가속하고 있습니다. 비만증은 체격 지수(BMI)가 30 이상인 것을 특징으로 하고, 식생활의 혼란, 운동 부족, 가공 식품의 과잉 섭취 등의 요인에 의해 증가하고 있습니다. 이러한 상태는 만성 염증, 인슐린 저항성, 카르티노이드 아이의 분비를 촉진합니다. 예를 들어, 미국 질병 예방 관리 센터(CDC)에 의하면, 2022년에는 미국의 22주에서 성인의 비만율이 35% 이상으로 보고되어, 2021년의 19주로부터 증가했습니다.

신경내분비 종양의 검출에 있어 진보도 시장 성장에 중요한 역할을 하고 있습니다. 2023년 10월, 써모 피셔 사이언티픽은 FDA 승인을 받은 최초의 크로모그라닌 A 테스트인 써모 사이언티픽 B*R*A*H*M*S CgA II 크립터 면역 분석법에 대한 FDA 허가를 받았습니다. 이 완전 자동화 검사는 위장 췌장 신경내분비 종양(GEP-NET) 환자의 CgA 수준을 측정하고 종양 진행 모니터링 및 치료 효과를 평가하는 데 도움이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 카르티노이드 종양 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 카르티노이드 종양 시장 : 성장률 분석
• 세계의 카르티노이드 종양 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 카르티노이드 종양 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 카르티노이드 종양 전체 시장(TAM)

제6장 시장 세분화

• 세계의 카르티노이드 종양 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 위장관 신경내분비 종양
• 췌장 신경내분비 종양
• 폐 신경내분비 종양
• 기타 질환 유형
• 세계의 카르티노이드 종양 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 옥트레오티드
• 란레오티드
• 텔로트리스타트 에틸
• 카페시타빈(셀로다)
• 5-플루오로우라실(5-FU)
• 독소루비신(아드리아마이신)
• 에토포사이드(VP-16)
• 다카바진(DTIC)
• 스트렙토조신
• 기타 치료법
• 세계의 카르티노이드 종양 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 비경구
• 기타 투여 경로
• 세계의 카르티노이드 종양 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 온라인 채널
• 오프라인 채널
• 세계의 카르티노이드 종양 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 및 진료소
• 학술기관
• 연구기관
• 세계의 카르티노이드 종양 시장 : 위장관 신경내분비 종양 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소장 신경내분비 종양
• 대장 신경내분비 종양
• 맹장 신경내분비 종양
• 세계의 카르티노이드 종양 시장 : 췌장 신경내분비 종양 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 인슐린종
• 비인슐린종
• 글루카고노마
• 세계의 카르티노이드 종양 시장 : 폐 신경내분비 종양 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 전형적인 카르티노이드 종양
• 비정형 카르티노이드 종양
• 세계의 카르티노이드 종양 시장 : 기타 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 흉선 신경내분비 종양
• 난소 신경내분비 종양

제7장 지역별/국가별 분석

• 세계의 카르티노이드 종양 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 카르티노이드 종양 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 카르티노이드 종양 시장 : 경쟁 구도
• 카르티노이드 종양 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Siemens Healthineers AG
• Boston Scientific Corporation
• Boehringer Ingelheim International GmbH
• Catalent Inc
• Ipsen SA
• Exelixis Inc
• Novocure Limited
• Hutchison MediPharma Limited(A subsidiary of HUTCHMED)
• Tarveda Therapeutics Inc.
• Lexicon Pharmaceuticals Inc.
• Dauntless Pharmaceuticals Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 카르티노이드 종양 시장(2029년) : 새로운 기회를 제공하는 국가
• 카르티노이드 종양 시장(2029년) : 새로운 기회를 제공하는 부문
• 카르티노이드 종양 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

A carcinoid tumor is a rare, slow-growing neuroendocrine tumor that typically develops in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms vary depending on the tumor's location and whether it secretes hormones, potentially leading to carcinoid syndrome.

The primary types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other disease types. Gastrointestinal neuroendocrine tumors (GI NETs) arise from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatment options include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered via oral and parenteral routes. These treatments are distributed through both online and offline channels and are utilized by hospitals, clinics, academic institutions, and research organizations.

The carcinoid tumor market research report is one of a series of new reports from The Business Research Company that provides carcinoid tumor market statistics, including the carcinoid tumor industry global market size, regional shares, competitors with the carcinoid tumor market share, detailed carcinoid tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the rising incidence of neuroendocrine tumors, increased awareness of rare cancers, improvements in healthcare infrastructure, the availability of targeted therapies, and the expansion of clinical trials for new treatment options.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth during the forecast period can be attributed to the rising demand for personalized medicine, a greater focus on early detection and diagnosis, increased adoption of minimally invasive surgeries, expanding research on novel therapies, and the growing use of molecular targeted therapies. Key trends expected in this period include the integration of AI and machine learning in diagnostics, a shift toward combination therapies, the expansion of telemedicine and remote monitoring, a focus on patient-centric care, and increased collaborative research efforts.

The increasing prevalence of obesity is driving the growth of the carcinoid tumor market. Obesity, characterized by a body mass index (BMI) of 30 or higher, is rising due to factors such as poor dietary habits, lack of physical activity, and excessive consumption of processed foods. This condition promotes chronic inflammation, insulin resistance, and the secretion of growth factors that contribute to tumor development, including carcinoid tumors. For example, according to the Centers for Disease Control and Prevention (CDC), in 2022, 22 U.S. states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. As obesity rates continue to rise, the incidence of obesity-related cancers, including carcinoid tumors, is expected to increase, further expanding the market.

Advancements in neuroendocrine tumor detection are also playing a crucial role in market growth. Companies are developing innovative diagnostic tools, such as fully automated chromogranin A (CgA) tests, to enhance early detection and improve treatment outcomes. In October 2023, Thermo Fisher Scientific received FDA clearance for the Thermo Scientific B*R*A*H*M*S CgA II KRYPTOR immunoassay, the first FDA-approved chromogranin A test. This fully automated test measures CgA levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), helping monitor tumor progression and assess treatment efficacy. By utilizing TRACE technology, the test provides precise results in under 30 minutes, replacing manual laboratory-developed tests and improving diagnostic accuracy and efficiency.

In April 2022, SERB Pharmaceuticals acquired the European commercialization rights for Xermelo (telotristat ethyl) from Ipsen. Xermelo is a treatment for carcinoid syndrome diarrhea, a symptom of carcinoid tumors. This acquisition strengthens SERB's portfolio of treatments for rare diseases and expands access to improved therapeutic options outside the U.S. and Japan. Ipsen, a France-based biopharmaceutical company, continues to focus on developing treatments for carcinoid syndrome and other rare cancers, contributing to the overall growth of the market.

Major players in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carcinoid tumor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carcinoid Tumor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carcinoid tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carcinoid tumor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carcinoid tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types
• 2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Online Channel; Offline Channel
• 5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations
• Subsegments:
• 1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors
• 2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma
• 3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors
• 4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Carcinoid Tumor Market Characteristics

3. Carcinoid Tumor Market Trends And Strategies

4. Carcinoid Tumor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Carcinoid Tumor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Carcinoid Tumor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Carcinoid Tumor Market Growth Rate Analysis
• 5.4. Global Carcinoid Tumor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Carcinoid Tumor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Carcinoid Tumor Total Addressable Market (TAM)

6. Carcinoid Tumor Market Segmentation

• 6.1. Global Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Lung Neuroendocrine Tumor
• Other Disease Types
• 6.2. Global Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Octreotide
• Lanreotide
• Telotristat ethyl
• Capecitabine (Xeloda)
• 5-Fluorouracil (5-FU)
• Doxorubicin (Adriamycin)
• Etoposide (VP-16)
• Dacarbazine (DTIC)
• Streptozocin
• Other Treatments
• 6.3. Global Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Carcinoid Tumor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Carcinoid Tumor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Clinics
• Academic Institutions
• Research Organizations
• 6.6. Global Carcinoid Tumor Market, Sub-Segmentation Of Gastrointestinal Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Bowel Neuroendocrine Tumors
• Colorectal Neuroendocrine Tumors
• Appendiceal Neuroendocrine Tumors
• 6.7. Global Carcinoid Tumor Market, Sub-Segmentation Of Pancreatic Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulinoma
• Non-insulinoma
• Glucagonoma
• 6.8. Global Carcinoid Tumor Market, Sub-Segmentation Of Lung Neuroendocrine Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Typical Carcinoid Tumors
• Atypical Carcinoid Tumors
• 6.9. Global Carcinoid Tumor Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thymic Neuroendocrine Tumors
• Ovarian Neuroendocrine Tumors

7. Carcinoid Tumor Market Regional And Country Analysis

• 7.1. Global Carcinoid Tumor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Carcinoid Tumor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carcinoid Tumor Market

• 8.1. Asia-Pacific Carcinoid Tumor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carcinoid Tumor Market

• 9.1. China Carcinoid Tumor Market Overview
• 9.2. China Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carcinoid Tumor Market

• 10.1. India Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carcinoid Tumor Market

• 11.1. Japan Carcinoid Tumor Market Overview
• 11.2. Japan Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carcinoid Tumor Market

• 12.1. Australia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carcinoid Tumor Market

• 13.1. Indonesia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carcinoid Tumor Market

• 14.1. South Korea Carcinoid Tumor Market Overview
• 14.2. South Korea Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carcinoid Tumor Market

• 15.1. Western Europe Carcinoid Tumor Market Overview
• 15.2. Western Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carcinoid Tumor Market

• 16.1. UK Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carcinoid Tumor Market

• 17.1. Germany Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carcinoid Tumor Market

• 18.1. France Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carcinoid Tumor Market

• 19.1. Italy Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carcinoid Tumor Market

• 20.1. Spain Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carcinoid Tumor Market

• 21.1. Eastern Europe Carcinoid Tumor Market Overview
• 21.2. Eastern Europe Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carcinoid Tumor Market

• 22.1. Russia Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carcinoid Tumor Market

• 23.1. North America Carcinoid Tumor Market Overview
• 23.2. North America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carcinoid Tumor Market

• 24.1. USA Carcinoid Tumor Market Overview
• 24.2. USA Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carcinoid Tumor Market

• 25.1. Canada Carcinoid Tumor Market Overview
• 25.2. Canada Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carcinoid Tumor Market

• 26.1. South America Carcinoid Tumor Market Overview
• 26.2. South America Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carcinoid Tumor Market

• 27.1. Brazil Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carcinoid Tumor Market

• 28.1. Middle East Carcinoid Tumor Market Overview
• 28.2. Middle East Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carcinoid Tumor Market

• 29.1. Africa Carcinoid Tumor Market Overview
• 29.2. Africa Carcinoid Tumor Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Carcinoid Tumor Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Carcinoid Tumor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carcinoid Tumor Market Competitive Landscape And Company Profiles

• 30.1. Carcinoid Tumor Market Competitive Landscape
• 30.2. Carcinoid Tumor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Carcinoid Tumor Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Siemens Healthineers AG
• 31.6. Boston Scientific Corporation
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Catalent Inc
• 31.9. Ipsen S.A.
• 31.10. Exelixis Inc
• 31.11. Novocure Limited
• 31.12. Hutchison MediPharma Limited (A subsidiary of HUTCHMED)
• 31.13. Tarveda Therapeutics Inc.
• 31.14. Lexicon Pharmaceuticals Inc.
• 31.15. Dauntless Pharmaceuticals Inc.

32. Global Carcinoid Tumor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carcinoid Tumor Market

34. Recent Developments In The Carcinoid Tumor Market

35. Carcinoid Tumor Market High Potential Countries, Segments and Strategies

• 35.1 Carcinoid Tumor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Carcinoid Tumor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Carcinoid Tumor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료